Despite a compensated dose being administered, the colon protective activity of AZD3241 (inhibiting extracellular MPO) was not recapitulated in the current study, evident in the lack of improvement in experimental colitis symptoms and persistent intestinal inflammation after the mice were co-supplemented with DSS and AZD3241. This evidence concerns the gene MPO and colitis.